Anrotinib is a new type of anti-tumor targeted drug, which can effectively inhibit the receptor of vascular endothelial growth factor and thus play a role in the treatment of lung cancer, and can be clinically used to treat lung cancer. Through the use of Anrotinib, it can inhibit tumor angiogenesis and reduce the vascular supply of tumors, thus significantly reducing and inhibiting the growth and distant metastasis of tumor cells, and has obvious efficacy in both small cell lung cancer and non-small cell lung cancer. However, there will be nausea, abdominal pain, dizziness, liver function abnormality and other adverse reactions during the use of Anrotinib, so the drug should be used in accordance with the standardized use of specialist doctor’s prescription, the emergence of adverse reactions should be promptly consult the doctor, and the use of the drug is prohibited for those who are allergic to the drug.